Fragment-based discovery identifies low molecular weight molecules which make key interactions with their target binding site. Fragments provide a range of efficient starting points from which potent ligands, and eventually drugs, can be developed.
Traditional fragment screening
Over the past decade, Vernalis has developed its proprietary library of fragments, successfully applied to more than 20 targets. Our library is typically screened using NMR spectroscopy, with the structure of bound fragments determined by X-ray crystallography (Hubbard, R. E. et al., Curr. Top. Med. Chem. 2007).
Fragment DEL screening
Fragment DEL Screening combines its sensitivity in DNA sequences and linker photo-labeling to extend its application to fragment discovery. HitGen Fragment DEL consists of >30,000 fragments and the selection inherit DEL selection efficiency and cost effectiveness.
For more details, please refer to Fragment DEL Selection.